Tag Archive for: compass pathways

Psychedelic Business Spotlight – May 6

,
This week in psychedelic business news: Wesana Health pivots strategy; Compass Pathways makes progress on anorexia; Completion launches psychedelic VR NFTs.
Shutterstock

Compass Pathways Shares ‘Promising’ Data That Psilocybin May Treat Anorexia

,
There is currently no FDA-approved treatment for anorexia. Could psychedelics be the answer?
Kevin O’Leary Thinks 3 Biggest Psychedelic Companies Will Merge, But Should They?Shutterstock

Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?

,
Our resident Psychedelic Investor James Hallifax wonders if the "Shark Tank" star's prediction makes financial sense.
5 Most Important Psychedelic Clinical Trials of 2022Shutterstock

5 Most Important Psychedelic Clinical Trials in 2022

Here's why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.

Psychedelic Business Spotlight – March 25

,
This week in psychedelic business news: Filament Health scores 2nd psilocybin patent; a new psychedelics company emerges as one crumbles.
Top 5 Most Influential Psychedelic StudiesShutterstock

Top 5 Most Influential Psychedelic Studies

We unpack five of the most important psychedelic studies conducted in recent years as psychedelics become mainstream medicine.
My Favorite Psychedelic Stocks Part 1Shutterstock

My Favorite Psychedelic Stocks: Part 1

,
Our resident Psychedelic Investor details five companies he thinks are in strong position to win the psychedelic medicine race.
DMT Vape Pen Patent Illustrates a Big Problem in the Psychedelics IndustryShutterstock

DMT Vape Pen Patent Illustrates a Big Problem in the Psychedelics Industry

Problematic patents have serious implications for the entire psychedelics industry.
Psychedelic Business Spotlight – December 17

Psychedelic Business Spotlight – December 17

,
This week in psychedelic business news: Cybin steps closer to a new patent; MindMed appoints new CEO; MAPS and Wesana Health resume negotiations.

Compass Pathways Study Finds SSRI Drugs Did Not Impede Psilocybin’s Therapeutic Effect

Chief Medical Officer Guy Goodwin calls study "a strong signal that COMP360 psilocybin therapy could be an adjunctive treatment to SSRI antidepressant as well as a monotherapy."